Replies to post #212766 on Biotech Values

[swampboots]

Engineered toxin bodies? Seems to me it needs funding but is it an investment or a tax loss first?


http://cancerres.aacrjournals.org/content/75/15_Supplement/2477

[biocqr]

MTEM > recent developments...

Molecular Templates Announces Agreement with Takeda for the Joint Development of a Protein-Based Oncology Therapy

Under the terms of the agreement, Takeda will make an upfront payment of $30 million and Molecular Templates is eligible to receive development, regulatory and commercial milestone payments of up to $632.5 million if Molecular Templates exercises its co-development option or $337.5 million if Molecular Templates does not exercise or opts out of its co-development option. Takeda has also agreed to pay royalties on sales of the commercial product developed through the collaboration. Molecular Templates and Takeda will share equally in the development costs.

Molecular Templates, Inc. Announces Closing of Public Offering of Common Stock and the Full Exercise of the Underwriters’ Option to Purchase Additional Shares

September 25, 2018 at 4:30 PM EDT
AUSTIN, Texas, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the closing of its underwritten public offering of 9,430,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,230,000 additional shares of common stock, at a price to the public of $5.50 per share. The gross proceeds to Molecular from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Molecular, are expected to be approximately $52 million. All of the shares of common stock to be sold in the offering are being sold by Molecular.